The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis
Open accessAbstract
BACKGROUND: Roxadustat (FG-4592) is an oral inhibitor of hypoxia-inducible factor (HIF) prolyl hydroxylase that stimulates erythropoiesis and regulates iron metabolism. In phase 2 studies involving patients with chronic kidney disease, roxadustat increased levels of endogenous erythropoietin to within or near the physiologic range, along with increasing hemoglobin levels and improving iron homeostasis. Additional data are needed regarding the efficacy and safety of roxadustat for the treatment of anemia in patients with chronic kidney disease who are not undergoing dialysis. METHODS: In this phase 3 trial conducted at 29 sites in China, we randomly assigned 154 patients with chronic kidney disease in a 2:1 ratio to receive roxadustat or placebo three times a week for 8 weeks in a double-blind manner. All the patients had a hemoglobin level of 7.0 to 10.0 g per deciliter at baseline. The randomized phase of the trial was followed by an 18-week open-label period in which all the patients received roxadustat; parenteral iron was withheld. The primary end point was the mean change from baseline in the hemoglobin level, averaged over weeks 7 through 9. RESULTS: During the primary-analysis period, the mean (±SD) change from baseline in the hemoglobin level was an increase of 1.9±1.2 g per deciliter in the roxadustat group and a decrease of 0.4±0.8 g per deciliter in the placebo group (P<0.001). The mean reduction from baseline in the hepcidin level (associated with greater iron availability) was 56.14±63.40 ng per milliliter in the roxadustat group and 15.10±48.06 ng per milliliter in the placebo group. The reduction from baseline in the total cholesterol level was 40.6 mg per deciliter in the roxadustat group and 7.7 mg per deciliter in the placebo group. Hyperkalemia and metabolic acidosis occurred more frequently in the roxadustat group than in the placebo group. The efficacy of roxadustat in hemoglobin correction and maintenance was maintained during the 18-week open-label period. CONCLUSIONS: In Chinese patients with chronic kidney disease who were not undergoing dialysis, those in the roxadustat group had a higher mean hemoglobin level than those in the placebo group after 8 weeks. During the 18-week open-label phase of the trial, roxadustat was associated with continued efficacy. (Funded by FibroGen and FibroGen [China] Medical Technology Development; ClinicalTrials.gov number, NCT02652819.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prolyl hydroxylase inhibitors or HIF stabilizers, now tested in chronic kidney disease, by increasing HIF-2α might target two abnormal processes enhancing both erythropoietin synthesis and iron absorption.134”
From Iron metabolism and iron disorders revisited in the hepcidin era (2020) · cites this paper as [134]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of Chronic Kidney Disease in the United States
Coresh, J., Selvin, E., Stevens, L. A., Manzi, J., Kusek, J. W., Eggers, P., Van Lente, F., & Levey, A. S. (2007) · JAMA · doi:10.1001/jama.298.17.2038 · Cited by 4,895
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Self-citationPrevalence of chronic kidney disease in China: a cross-sectional survey
Zhang, L., Wang, F., Wang, L., Wang, W., Liu, B., Liu, J., Chen, M., He, Q., Liao, Y., Yu, X., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60033-6 · Cited by 2,104
Self-citationA trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. W. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,094
Ganz, T., & Nemeth, E. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.01.014 · Cited by 1,282
Eschbach, J. W., Abdulhadi, M. H., Browne, J. K., Delano, B. G., Downing, M. R., Egrie, J. C., Evans, R. W., Friedman, E. A., Graber, S. E., Haley, N. R., et al. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-12-992 · Cited by 795
Regulation of Iron Metabolism by Hepcidin
Nemeth, E., & Ganz, T. (2006) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.26.061505.111303 · Cited by 756
Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs)
Peyssonnaux, C., Zinkernagel, A. S., Schuepbach, R. A., Rankin, E., Vaulont, S., Haase, V. H., Nizet, V., & Johnson, R. S. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31370 · Cited by 639
Flagged first, then by citations
Research works printed but not linked: 3
- Zhu LN, Lv W, Teng J, et al. Association of residual renal function at initiation of dialysis with prognosis in maintenance dialysis patients. Chin J Nephrol 2012:757-764.
- Collins AJ. Anaemia management prior to dialysis: cardiovascular and cost-benefit observations. Nephrol Dial Transplant 2003;18:Suppl 2:ii2-ii6.12819293
- KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1-150 (https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf).
Cited by
Sorted by citations
Items 301–400 of 584
Nasiri, H., Mirmazhari, A., Mirzakhani, L., Asgarian, P., Gholibeigi, A., Ghandali, T., Moghaddam, M. T., Mohammadi, M., Karimi, M., & Makhlough, A. (2025) · BMC Nephrology · doi:10.1186/s12882-025-04561-x · Cited by 8
Chong, S., Xie, Q., Ma, T., Xiang, Q., Zhou, Y., & Cui, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.967532 · Cited by 8
Tubulovascular protection from protease-activated receptor-1 depletion during AKI-to-CKD transition
Lok, S. W. Y., Yiu, W. H., Zou, Y., Xue, R., Li, H., Ma, J., Chen, J., Chan, L. Y. Y., Lai, K. N., & Tang, S. C. W. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad051 · Cited by 8
Self-citationA critical review of Roxadustat formulations, solid state studies, and analytical methodology
Mahajan, R., Samanthula, G., Srivastava, S., & Asthana, A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e16595 · Cited by 8
Wang, X., Wei, C., Zhao, D., Sun, X., Zhu, F., Mei, Y., Ma, Q., Cai, G., Chen, X., & Li, P. (2023) · Kidney Diseases · doi:10.1159/000533304 · Cited by 8
Investigational new drugs for the treatment of chronic renal failure: an overview of the literature
Terzo, C., Gembillo, G., Cernaro, V., Longhitano, E., Calabrese, V., Casuscelli, C., Peritore, L., & Santoro, D. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2326624 · Cited by 8
Troise, D. E., Infante, B., Mercuri, S., Piccoli, C., Lindholm, B., & Stallone, G. (2024) · Antioxidants · doi:10.3390/antiox13050537 · Cited by 8
Chen, Y., Ohara, T., Hamada, Y., Wang, Y., Tian, M., Noma, K., Tazawa, H., Fujisawa, M., Yoshimura, T., & Matsukawa, A. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04067-3 · Cited by 8
Mohrin, M. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.01.034 · Cited by 9
Anemia: A Connection Between Heart Failure and Kidney Failure
Locatelli, F., Vecchio, L. D., Minutolo, R., & Nicola, L. D. (2021) · Cardiology Clinics · doi:10.1016/j.ccl.2021.04.003 · Cited by 8
Zhao, L., Han, Q., Zhou, L., Bai, L., Wang, Y., Wu, Y., Ren, H., Zou, Y., Li, S., Su, Q., et al. (2022) · Renal Failure · doi:10.1080/0886022x.2021.2009862 · Cited by 8
WT1: The Hinge Between Anemia Correction and Cancer Development in Chronic Kidney Disease
Lee, W., Chiu, C.-H., Chu, T., & Chien, Y.-S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.876723 · Cited by 8
Mechanism of Cornus Officinalis in Treating Diabetic Kidney Disease Based on Network Pharmacology
Zhang, Y., Jin, D., Zhou, R., Yang, C., Zhang, Y.-H. H., Lian, F., & Tong, X. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/1799106 · Cited by 8
Prolyl Hydroxylase Inhibition Mitigates Allograft Injury During Liver Transplantation
Harnoss, J. M., Cai, J., Hinterkopf, S., Radhakrishnan, P., Schmitt, A., Dupovac, M., Nees, L. K., Strowitzki, M. J., Taylor, C. T., & Schneider, M. A. (2022) · Transplantation · doi:10.1097/tp.0000000000004258 · Cited by 8
Grzeszczak, W., Szczyra, D., & Śnit, M. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18041612 · Cited by 8
Liu, C., Fu, Z., Jiang, J., Chi, K., Geng, X., Mao, Z., Song, C., Sun, G., Hong, Q., Cai, G., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.724456 · Cited by 8
Self-citationCurrent clinical profiles for Chinese hemodialysis patients
Zhao, X., Ma, C., Gan, L., Hou, F. F., Liang, X., Chen, X., Ni, Z., Chen, Y., Li, X., Guo, W., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-11951-6 · Cited by 7
Self-citationHypoxia, ROS, and HIF Signaling in I/R Injury: Implications and Future Prospects
Singh, M. K., Yun, H. R., Ranbhise, J. S., Han, S., Kim, S. S., & Kang, I. (2026) · Antioxidants · doi:10.3390/antiox15020153 · Cited by 9
Chou, Y., Pan, S., & Lin, S. (2022) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.118 · Cited by 9
iHypoxia: An Integrative Database of Protein Expression Dynamics in Response to Hypoxia in Animals
Liu, Z., Wang, P., Zhang, Q., Li, S., Zhang, Y., Guo, Y., Jia, C., Shao, T., Li, L., Cheng, H., et al. (2022) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.12.001 · Cited by 7
Self-citationFaivre, A., Dissard, R., Kuo, W., Verissimo, T., Legouis, D., Arnoux, G., Heckenmeyer, C., Fernandez, M., Tihy, M., Rajaram, R. D., et al. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad075 · Cited by 7
Next-generation therapy for lower-risk MDS
Sébert, M. (2023) · Hematology · doi:10.1182/hematology.2023000520 · Cited by 7
Ishiyama, Y., Yagisawa, T., Ichioka, M., Hagiwara, A., Shimizu, T., Omoto, K., Nozaki, T., Inui, M., Ino, J., Takeda, K., et al. (2024) · Transplantation Proceedings · doi:10.1016/j.transproceed.2024.05.029 · Cited by 7
Wang, R., Gomez-Salazar, M. A., Cervera, I. P., Coutts, A. S., French, K. L., Pinto, M. M., Gohlke, S., García-Martín, R., Blüher, M., Schofield, C. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51718-7 · Cited by 7
Randomized Trial of Pegmolesatide for the Treatment of Anemia in Patients With Nondialysis CKD
Xie, J., Yang, A., Qiu, H., Peng, X., Lu, W., Huang, X., Chen, Q., Zhong, A., Tang, S., Wang, Q. L., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.12.002 · Cited by 7
Self-citationProlyl Hydroxylase Inhibition Mitigates Pouchitis
Harnoss, J. M., Gebhardt, J. M., Radhakrishnan, P., Leowardi, C., Burmeister, J., Halligan, D. N., Yuan, S., Kennel, K. B., Strowitzki, M. J., Schaible, A., et al. (2019) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izz218 · Cited by 8
Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
Chanias, I., Stojkov, K., Stehle, G., Daskalakis, M., Simeunovic, H., Njue, L. M., Schnegg-Kaufmann, A. S., Porret, N. A., Allam, R., Rao, T. N., et al. (2021) · Cancers · doi:10.3390/cancers13133296 · Cited by 7
Targeting ineffective hematopoiesis in myelodysplastic syndromes
Patnaik, M. M., & Santini, V. (2021) · American Journal of Hematology · doi:10.1002/ajh.26416 · Cited by 7
Anaemia in chronic kidney disease: what do new generation agents offer?
Tonelli, M. A., & Thadhani, R. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00120-9 · Cited by 7
The HIF-prolyl hydroxylases have distinct and nonredundant roles in colitis-associated cancer
Kennel, K. B., Burmeister, J., Radhakrishnan, P., Giese, N. A., Giese, T., Salfenmoser, M., Gebhardt, J. M., Strowitzki, M. J., Taylor, C. T., Wielockx, B., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153337 · Cited by 7
Chen, J., Zhang, Y., Luo, C., Ren, Y., Ye, B., Hu, X., Li, Y., Zhu, B., He, Q., & Shao, L. (2022) · Translational Andrology and Urology · doi:10.21037/tau-22-709 · Cited by 7
Self-citationAnemia renal: tratamientos actuales y moléculas emergentes
Heras, M. (2023) · Revista Clínica Española · doi:10.1016/j.rce.2023.04.005 · Cited by 7
Ariyeloye, S., Kämmerer, S., Klapproth, E., Wielockx, B., & El‐Armouche, A. (2024) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-024-02921-4 · Cited by 7
Chen, Y., Wen, P., Yang, J., & Niu, J. (2020) · Kidney Diseases · doi:10.1159/000505156 · Cited by 7
Anemia management in dialysis patients
Nair, S., & Trivedi, M. (2020) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000607 · Cited by 7
Heritable disorders of oxygen sensing
Semenza, G. L. (2021) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62250 · Cited by 7
Zhang, Q., Li, W., Ayidaerhan, N., Han, W., Chen, Y., Song, W., & Yue, Y. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16546 · Cited by 8
Activation of the hypoxia response pathway protects against age-induced cardiac hypertrophy
Röning, T., Magga, J. M., Laitakari, A., Halmetoja, R., Tapio, J., Dimova, E. Y., Szabó, Z., Rahtu‐Korpela, L., Kemppi, A., Walkinshaw, G., et al. (2021) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2021.12.003 · Cited by 7
Heritable disorders of oxygen sensing
Semenza, G. L. (2021) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.62521 · Cited by 7
Takada, A., Shibata, T., Shiga, T., Ugawa, T., Komatsu, K., & Akizawa, T. (2022) · Drug Metabolism and Pharmacokinetics · doi:10.1016/j.dmpk.2022.100461 · Cited by 7
Effects of Roxadustat on Thyroid Profiles in Patients and Animals with Chronic Kidney Disease
Li, W., Cao, T., Huang, G., Guo, J., Zhu, T., Hu, H., Huang, H., Liu, X., Wu, L., Chen, J., et al. (2024) · American Journal of Nephrology · doi:10.1159/000542699 · Cited by 6
Self-citationLiang, X., Huang, R., Xie, J., Zhang, Y.-N., Li, Y., Chen, X., Guan, T., Zhou, H., Fu, P., Liao, Y., et al. (2024) · Kidney Diseases · doi:10.1159/000543193 · Cited by 6
Self-citationMa, X., Pai, P. M., Zhu, W., Chen, X., & Cui, L. (2024) · CEN Case Reports · doi:10.1007/s13730-024-00865-3 · Cited by 6
The role of hypoxia in chronic kidney disease: a nuanced perspective
Faivre, A., & de Seigneux, S. (2024) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000989 · Cited by 6
Liu, J., Meng, Z., Feng, L., Zhuo, L., Liang, Y., Yang, M., Su, L., Zheng, Z., Liu, B., & Ren, J. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf061 · Cited by 6
Self-citationWang, L., Yin, H., Yang, L., Zhang, F., Wang, S., & Liao, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.779694 · Cited by 6
Zhang, L., Liu, Y., Huang, Y., Zhao, Y., Wei, C., Yang, K., Li, X., Zhang, S., Wang, W., Liu, Y., et al. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-4344 · Cited by 6
HYDROLYTIC DEGRADATION STUDY OF ROXADUSTAT BY RP-HPLC AND HPTLC
Damle, M. C., & Sonule, J. A. (2023) · International Journal of Pharmacy and Pharmaceutical Sciences · doi:10.22159/ijpps.2023v15i8.48355 · Cited by 6
Prolyl hydroxylase inhibitors: a breath of fresh air for diabetic kidney disease?
Forbes, J. M. (2020) · Kidney International · doi:10.1016/j.kint.2020.01.038 · Cited by 6
Qin, X., Wu, K., Zuo, C., & Lin, M. (2020) · Current Eye Research · doi:10.1080/02713683.2020.1805470 · Cited by 6
Shinozaki, Y., Fukui, K., Kobayashi, H., Yoshiuchi, H., Matsuo, A., & Matsushita, M. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173990 · Cited by 6
Anemia of chronic kidney disease: Will new agents deliver on their promise?
Souaid, T., Taliercio, J. J., Simon, J. F., Mehdi, A., & Nakhoul, G. (2022) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.89a.21100 · Cited by 6
Hou, Y., Wang, C., Mao, X.-Y., Zhang, M.-Z., & Li, B. (2022) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2022.06.008 · Cited by 8
Self-citationRenal anemia: current treatments and emerging molecules
Heras, M. (2023) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2023.06.006 · Cited by 6
Tuffs, C., Dupovac, M., Richter, K., Holten, S., Schaschinger, T., Marg, O., Poljo, A., Tasdemir, A. N., Harnoss, J. M., Billeter, A. T., et al. (2024) · American Journal Of Pathology · doi:10.1016/j.ajpath.2024.10.018 · Cited by 5
Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
Zhu, X., Zhang, C., Xu, T., Jiang, G.-N., & Li, Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i26.7682 · Cited by 5
Roxadustat induces hepatotoxicity in zebrafish embryos via inhibiting Notch signaling
Yang, D., Xiao, J., Wan, M., Liu, J., Huang, L., Li, X., Zhang, L., Liu, F., Liang, D., Zheng, Y., et al. (2023) · Journal of Applied Toxicology · doi:10.1002/jat.4444 · Cited by 5
Tamaki, M., Inagaki, T., Minato, M., Shibata, E., Nishioka, R., Nishioka, S., Matsubara, Y., Sasaki, M., Tamaki, M., Tamaki, M., et al. (2024) · Internal Medicine · doi:10.2169/internalmedicine.3773-24 · Cited by 5
Kile, M., & Sudchada, P. (2020) · International Urology and Nephrology · doi:10.1007/s11255-020-02584-x · Cited by 5
Demandt, J. A. F., van Kuijk, K., Theelen, T. L., Marsch, E., Heffron, S. P., Fisher, E. A. A., Carmeliet, P., Biessen, E. A. L., & Sluimer, J. C. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.664258 · Cited by 7
Oxygen sensing, anaesthesia and critical care: a narrative review
Slingo, M., & Pandit, J. J. (2021) · Anaesthesia · doi:10.1111/anae.15582 · Cited by 5
Ko, V. H., Yu, L. J., Secor, J. D., Pan, A., Mitchell, P. D., Kishikawa, H., & Puder, M. (2021) · The FASEB Journal · doi:10.1096/fj.202002661rr · Cited by 5
Tapio, J., Halmetoja, R., Dimova, E. Y., Mäki, J. M., Laitala, A., Walkinshaw, G., Myllyharju, J., Serpi, R., & Koivunen, P. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102222 · Cited by 5
Chen, T., Huang, J., Dong, H., Xu, L., Chen, C., Tang, Y., & Huang, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1029432 · Cited by 5
How I Manage Transplant Ineligible Patients with Myelodysplastic Neoplasms
Gurnari, C., Xie, Z., & Zeidan, A. M. (2022) · Clinical Hematology International · doi:10.1007/s44228-022-00024-4 · Cited by 6
Liang, Q., Li, X., Niu, Q., Zhao, H., & Zuo, L. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072450 · Cited by 5
Self-citationVenugopal, S., Shallis, R. M., & Zeidan, A. M. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2238897 · Cited by 6
Beyond HMAs: Novel Targets and Therapeutic Approaches
Getz, T. M., Bewersdorf, J. P., Kewan, T. Z., Stempel, J. M., Bidikian, A., Shallis, R. M., Stahl, M. F., & Zeidan, A. M. (2024) · Seminars in Hematology · doi:10.1053/j.seminhematol.2024.08.001 · Cited by 5
Cheng, Y., Yang, Q., Feng, B., Yang, X., & Jin, H. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1503477 · Cited by 5
Emrich, I. E., Böhm, M., & Heine, G. H. (2020) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1133-7849 · Cited by 5
Yamazaki, T., Mimura, I., Kurata, Y., Tanaka, T., & Nangaku, M. (2023) · Physiological Reports · doi:10.14814/phy2.15810 · Cited by 5
Busti, F., Marchi, G., Vianello, A., & Girelli, D. (2020) · Internal and Emergency Medicine · doi:10.1007/s11739-020-02417-w · Cited by 5
Zhang, Y., Ren, S., Xue, H., Wang, Y., Zou, Y., Cai, Y., He, J., Yuan, X., Jiang, F., Wei, J., et al. (2021) · BMC Nephrology · doi:10.1186/s12882-021-02229-w · Cited by 5
Self-citationLoenarz, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201913263 · Cited by 5
Are we approaching a new era in the treatment of anemia of chronic kidney disease patients?
Locatelli, F., & Vecchio, L. D. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.09.119 · Cited by 5
Li, J., Huang, K., McBride, F., Sadagopan, A., Gallant, D. S., Thakur, M., Khanna, P., Li, B., Ge, M., Weiss, C. N., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.08.09.607311 · Cited by 5
Miguel, P. M., Fernández-Antón, E., Rodríguez-Puyol, D., de Abajo, F. J., & López‐Ongil, S. (2025) · Pharmaceuticals · doi:10.3390/ph18101566 · Cited by 4
Roxadustat: A catalyst for diabetic wound healing through re-epithelialization and angiogenesis
Tang, D., Lin, Q., Xu, K., & Lu, Q. (2025) · CytoJournal · doi:10.25259/cytojournal_235_2024 · Cited by 4
Zhang, Z., Liu, J., Kang, Y., Liu, Y., & Fu, P. (2025) · Kidney Diseases · doi:10.1159/000548711 · Cited by 4
Roxadustat for renal anemia: current clinical experience
Ji, J., Li, Z., Fang, S., & Li, Z. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1712869 · Cited by 4
Liu, J., Li, S., Yang, F., Li, T., Li, R., Waheed, Y. A., Chen, M., Li, S., Liu, K., Tong, Y., et al. (2024) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.520 · Cited by 4
Li, P., Sun, X., Zhang, L., Lin, H., Wang, N., Li, Y., Zhao, S., Fu, P., Cheng, H., Guo, Z., et al. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.01.027 · Cited by 4
Self-citationKaur, H., Pandey, N. O., Chandaluri, L., Shaaban, N., Martinez, A. E., Kidder, E. J., Patel, V. J., Kshirsagar, S. G., Kumar, D., Frausto, L., et al. (2025) · Experimental Neurology · doi:10.1016/j.expneurol.2025.115181 · Cited by 6
Du, X., Wang, Y., Yu, H., Yang, J., He, W., Wang, Z., Zheng, D., Li, X., Shen, S., Sun, D., et al. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003672 · Cited by 4
Self-citationDiabetic Kidney Disease: From Pathophysiology to Treatment Perspectives
Varda, L., Vreča, N., Ekart, R., Bevc, S., & Piko, N. (2026) · Kidney & Blood Pressure Research · doi:10.1159/000550085 · Cited by 9
Zhao, D., Chang, Z., Han, Q., Wang, Q., Zhai, Y., Sun, M., 蔡灯塔, Zhang, L., Zheng, X., & Wang, Y. (2026) · The FASEB Journal · doi:10.1096/fj.202600149r · Cited by 4
Wyatt, C. M., & Drüeke, T. B. (2020) · Kidney International · doi:10.1016/j.kint.2019.12.005 · Cited by 4
Is HIF-PHI the Answer to Tackle ESA Hyporesponsiveness in the Elderly?
Wu, H. H. L., Chinnadurai, R., & Walker, R. J. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2030040 · Cited by 4
You, X., Guo, B., Wang, Z., Ma, H., Liu, L., Zhou, R., Zheng, Y., & Zhang, X. (2023) · Molecular Omics · doi:10.1039/d3mo00015j · Cited by 4
Detection of FG‐4592 and metabolites in equine plasma, urine and hair following oral administration
Cutler, C., Viljanto, M., Taylor, P., Hincks, P. R., Habershon‐Butcher, J., Gray, B. P., & Scarth, J. P. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3643 · Cited by 4
Unveiling the role of hypoxia-inducible factor 2alpha in osteoporosis: Implications for bone health
Wang, L., Lu, Z., Luo, S., Li, Y., Yang, Z., & Lu, H. (2024) · World Journal of Stem Cells · doi:10.4252/wjsc.v16.i4.389 · Cited by 5
Central hypothyroidism caused by roxadustat
Hauge, J. W., Wærp, C. M., Hofsø, D., & Abedini, S. (2024) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.24.0319 · Cited by 5
Introduction to a review series on normal and pathologic erythropoiesis
Cazzola, M. (2022) · Blood · doi:10.1182/blood.2022015497 · Cited by 4
Wang, A. Y.-M., An, Y., Cai, G., Chen, J., Chen, W., Chen, X., Cui, Z., Hao, C., Hou, F. F., Liu, B., et al. (2021) · Springer eBooks · doi:10.1007/978-3-030-56890-0_20 · Cited by 4
Self-citationWen, Y., Xu, Y. Y., Tian, H., Jiang, S., Jiang, G., & Li, P. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.783387 · Cited by 4
Su, H., Yi, J., Tsui, C. K. M., Li, C., Zhu, J., Li, L., Zhang, Q., Zhu, Y., Xu, J., Zhu, M., et al. (2022) · Future Microbiology · doi:10.2217/fmb-2022-0050 · Cited by 4
Current Therapeutic Landscape in Lower Risk Myelodysplastic Syndromes
Wang, C., & Sallman, D. A. (2023) · Current Treatment Options in Oncology · doi:10.1007/s11864-023-01062-7 · Cited by 4
Self-citationNakamura, N., Aso, S., Nakagawa, C., Tachibana, M., Fujikawa, A., Tsubouchi, K., Gunge, N., Miyazaki, T., Okabe, Y., Matsuzaki, H., et al. (2023) · Transplantation Proceedings · doi:10.1016/j.transproceed.2023.03.062 · Cited by 4
Yugavathy, N., Abdullah, B. M., Lim, S. K., Gafor, A. H. A., Wong, M. G., Bavanandan, S., Wong, H. S., & Huri, H. Z. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45080413 · Cited by 5
FG‐4592 protected haematopoietic system from ionising radiation in mice
Wang, Y., Cheng, Y., Zhang, P., Huang, D., Zhai, X., Feng, Z., Fang, D., Liu, C., Du, J., & Cai, J. (2024) · Immunology · doi:10.1111/imm.13797 · Cited by 4
Self-citation
Metadata
- Authors
- Chen, N., Hao, C., Peng, X., Lin, H., Yin, A., Hao, L., Tao, Y., Liang, X., Liu, Z., Xing, C., Chen, J., Luo, L., Zuo, L., Liao, Y., Liu, B.-C., Leong, R., Wang, C., Liu, C., Neff, T., Szczech, L., & Yu, K.-H. P.
- Affiliations
- Shanghai Jiao Tong University (CN)
- From the Department of Nephrology, Institute of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine (N.C.), and the Division of Nephrology, Huashan Hospital Fudan University (C.H.), Shanghai, the Department of Nephrology, People’s Hospital of Guangxi Zhuang Autonomous Region (X.P.), and the Department of Nephrology, First Affiliated Hospital of Guangxi Medical University (Y.L.), Nanning, the First Affiliated Hospital of Dalian Medical University, Dalian (H.L.), the...
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-09-12
- Volume
- 381
- Issue
- 11
- Pages
- 1001-1010
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2963534431
- Cited by
- 582
- References
- 32
- Citations by year
- 2026: 53 · 2025: 62 · 2024: 68 · 2023: 68 · 2022: 96 · 2021: 112 · 2020: 100 · 2019: 22
- FWCI
- 58.49
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- FibroGen
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Keywords
- roxadustat, chronic kidney disease, anemia of chronic kidney disease, HIF prolyl hydroxylase inhibitors, non-dialysis patients, hemoglobin increase, hepcidin, iron metabolism, erythropoiesis, hyperkalemia, metabolic acidosis, total cholesterol, Chinese patients, open-label extension
- MeSH terms
- Acidosis, Adult, Aged, Anemia, Cholesterol, Double-Blind Method, Female, Glycine, Hematinics, Hemoglobins, Humans, Hyperkalemia, Isoquinolines, Male, Middle Aged, Renal Insufficiency, Chronic, Hypoxia-Inducible Factor-Proline Dioxygenases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
